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Glucosylceramides (GlcCer) are involved in the regulation of Cryptococcus neoformans virulence. In the
present study, we demonstrate that passive immunization with a monoclonal antibody to GlcCer significantly
reduces host inflammation and prolongs the survival of mice lethally infected with C. neoformans, revealing a
potential therapeutic strategy to control cryptococcosis.
Cryptococcosis, a fungal infection caused by the yeast-like
pathogen Cryptococcus neoformans, is an important cause of
morbidity and mortality in immunosuppressed individuals, af-
fecting especially the central nervous system (3, 33). Treatment
failures occur and, despite high doses of antifungal drugs, the
fungus is frequently not eradicated, resulting in recurrent dis-
ease in individuals coinfected with human immunodeficiency
virus in the absence of continued antifungal therapy (3, 8).
Passive immunization with monoclonal antibodies (MAbs)
to cryptococcal antigens can protect mice against lethal C.
neoformans infections (6, 11, 13, 36). Targets of protective
MAbs include glucuronoxylomannan (GXM), the major cap-
sular polysaccharide of C. neoformans (6, 11, 13), the pigment
melanin (36), and the cell wall polysaccharide glucan (30).
Antibodies to GXM have been characterized as potential ther-
apeutic agents (6) and are in clinical trials for individuals with
cryptococcosis (18). In other models, passively administered
MAbs have protected mice against lethal infections with His-
toplasma capsulatum (26), Candida albicans (15), and Aspergil-
lus fumigatus (7). The mechanisms of MAb-mediated protec-
tion are complex and heterogeneous, but it appears that
passively administered antibodies enhance the effectiveness of
host immune cells (5, 13) or are directly antifungal (23, 35).
Glucosylceramides (GlcCer; cerebrosides; monohexosyl cer-
amides) are glycosphingolipids composed of a glucose unit
bound to a ceramide moiety via a glycosidic linkage. GlcCer
molecules are widely distributed among pathogenic fungi and
are extremely conserved structurally (1). This lipid, which is
present at the fungal plasma membrane (1), cell wall (23–25,
35), and secretory vesicles (34), induces antifungal antibodies
(23, 35) and regulates the virulence of C. neoformans in animal
infections (31). Based on the previously characterized ability of
antibodies to GlcCer to control the growth of C. neoformans in
vitro (35), we hypothesized that GlcCer-binding MAbs could
protect mice against lethal C. neoformans infections.
C. neoformans strain 24067 (serotype D) was obtained from
the American Type Culture Collection (Rockville, MD). C.
neoformans cultures were grown in Sabouraud broth for 2 days
at 30°C in a rotary shaker at 150 rpm, and cells were then
washed three times in phosphate-buffered saline (PBS), pH
7.2, and collected by centrifugation at 4,000  g (10 min, 4°C).
The MAb to GlcCer, a mouse immunoglobulin G2b (IgG2b)
with the ability to enhance the antifungal properties of mac-
rophages and promote direct antimicrobial activity, was pro-
duced as described previously (9, 23, 30, 36). Concentrated
antibody solutions were prepared from ascites of BALB/c mice
injected with antibody-producing hybridoma cells. Antibodies to
GlcCer were purified by Protein G affinity chromatography.
A/J mice (females, 6 to 8 weeks old; National Cancer Insti-
tute, Frederick, MD) were passively immunized with the puri-
fied MAb to GlcCer (100, 250, or 500 g per animal, admin-
istered intraperitoneally (i.p.); n  10 per group). This mouse
strain has been used by us and many other investigators as an
animal host susceptible to infection by C. neoformans (12, 22,
27, 37, 38). A/J mice are deficient in the production of the
complement component C5, which is involved in the efficient
control of initial steps of animal cryptococcosis (10). Twenty-
four hours after immunization, mice were infected intratrache-
ally (i.t.) with 1  106 C. neoformans cells. Mice (n  10 per
group) injected i.p. with PBS or a commercial unrelated IgG2b
prior to C. neoformans infections were used as control groups.
The survival times for the infected mice immunized with the
anti-GlcCer MAb and those for PBS- or irrelevant antibody-
treated mice were compared using log rank analysis (SPSS
14.0; SPSS Inc., Chicago, IL). P values of less than 0.05 were
considered significant. Mice were housed in the animal facility
of Albert Einstein College of Medicine, and all experimental
procedures adhered to protocols approved by the Animal Care
and Use Committee.
As demonstrated in Fig. 1, mice given the MAb to GlcCer
lived significantly longer than control mice given PBS or the
irrelevant IgG2b. Although the protective effects were more
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pronounced when a 500-g antibody dose was used, passive
immunization with 250 g of purified antibody also prolonged
mice survival. In other experiments, 100 g of the MAb to
GlcCer was not protective (data not shown).
For CFU, cytokine, and histological analyses, mice were given
500 g of a MAb (commercial IgG2b or the MAb to GlcCer) or
of PBS i.p. Twenty-four hours later, mice were infected i.t. with C.
neoformans (106 cells/mouse). Age-matched, noninfected mice
were used to provide baseline histology and cytokine values. An-
tibody or PBS-treated (n  5 per group) and noninfected mice
(n 1 per group) were sacrificed on days 1 and 7 after infection.
In all experimental groups, the right upper lobe of the lung was
removed and placed into formalin for histology. Formalin-fixed,
paraffin-embedded tissues were examined by hematoxylin-eosin
staining for evaluation of histopathology and fungal distribution.
The remaining tissue of each lung was homogenized in 4 ml of
PBS, and aliquots were plated on brain heart infusion agar sup-
plemented with penicillin-streptomycin, followed by incubation at
30°C for CFU determination. The remaining part of the suspen-
sion was centrifuged, and the supernatant was stored at 20°C.
When all samples had been collected, the supernatants from each
group at each time point were pooled and cytokine/chemokine
analyses were performed with a RayBio mouse cytokine antibody
array II kit (RayBiotech, Inc., Norcross, GA) according to the
manufacturer’s instructions. In this assay, cytokines and chemo-
kines are detected by interaction with antibodies specific to each
of the molecules measured. Cytokine samples were analyzed in
duplicate, and the experiment was repeated with similar results.
The membranes were developed radiographically, and ImageJ
(http://rsb.info.nih.gov/ij/) was used to analyze the results. Statis-
tical analyses and comparisons between the cytokine/chemokine
values of the control group and mice given anti-GlcCer were
performed using the Student t test.
A histological analysis of lung sections revealed that admin-
istration of antibody to GlcCer significantly reduced inflam-
mation (Fig. 2). On day 1, although increased cellularity, es-
pecially peribronchial inflammation, occurred in the lungs of
mice treated with antibody to GlcCer, there was greater pres-
ervation of alveolar airspace in those mice than in the controls.
C. neoformans yeast cells were clearly visible in the alveolae of
mice in all experimental groups. On day 7, increased numbers
of yeasts were seen in the air spaces, but there was a dramatic
reduction in inflammation in the lungs of mice treated with the
MAb to GlcCer, whereas dense inflammation persisted in the
control mice, and numerous multinucleated giant cells were
present. A comparison of the total number of cells in the lungs
of mice given PBS, the control MAb, or the MAb to GlcCer
revealed, for the last group, a significantly smaller number of
cells at both day 1 (P  0.05) and day 7 (P  0.01) after
infection, as statistically analyzed using analysis of variance. In
this early time range (1 to 7 days) of infection, the administra-
tion of MAb to GlcCer did not reduce the numbers of CFU in
the lungs of infected mice (data not shown).
Lung cytokine levels of mice treated with PBS, control MAb,
or MAb to GlcCer were measured on days 1 and 7 after
infection with C. neoformans (Fig. 3). On day 1 after infection,
interleukin-4 (IL-4), IL-12, IL-12p70 and RANTES (regulated
upon activation, normal T-cell expressed, and secreted pro-
tein) were detected in significantly higher levels (P  0.05) in
mice given GlcCer antibody, whereas the levels of other tested
cytokines were very similar between groups. On day 7 postin-
fection, mice given GlcCer antibody had significantly higher
pulmonary concentrations of IL-4, IL-6, IL-12, monocyte che-
moattractant protein 5 (MCP-5), and stem cell factor (P 
0.05).
GlcCer in pathogenic fungi was first described two decades
FIG. 1. Passive immunization with MAb to GlcCer prolongs survival of mice lethally infected with C. neoformans. Mice were given PBS,
irrelevant IgG2b (the control MAb), or a MAb to GlcCer prior to lethal i.t. infection with C. neoformans. Administration of the anti-GlcCer
antibody significantly prolonged mice survival (P  0.005 for the 500-g dose; P  0.03 for the 250-g dose).
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ago (20). These molecules have been fully characterized at the
structural level and found to be extremely conserved in a num-
ber of fungal species (reviewed in reference 1). Recently, there
have been several investigations of the roles of GlcCer in
fungal physiology and pathogenesis. For example, GlcCer was
characterized by different groups as the target of antimicrobial
antibodies (9, 23, 29, 35) and plant defensins (39). In addition,
the inhibition or inactivation of GlcCer synthase, the enzyme
responsible for the last step in GlcCer biosynthesis, resulted in
aberrant morphogenesis in different fungal models (19). In C.
neoformans, a direct relationship between GlcCer expression
and yeast replication was established by molecular and anti-
body-based approaches (31, 35). GlcCer also regulates fungal
virulence in animal models of cryptococcosis (31). Finally, this
lipid is a key component of secretory vesicles transporting
capsular polysaccharide (34). Given the clear relevance of
GlcCer in the biology and pathogenesis of C. neoformans, we
speculated that passive immunization of mice with GlcCer-
binding antibodies could have the potential to control crypto-
coccosis.
In the present study, we demonstrate that a MAb to GlcCer
protects mice against lethal C. neoformans infection. Although
protective antibodies to glycolipids in other microbes have
been described (16), this is, to our knowledge, the first dem-
onstration of protection using a MAb targeting a fungal glyco-
lipid. Preliminary analyses in our laboratory indicate that the
MAb to GlcCer, which binds to the cryptococcal cell wall, is
cytotoxic in vitro (25, 35) but does not opsonize C. neoformans
cells in vitro (unpublished data), possibly because of a masking
of the Fc domains by capsular polysaccharides. Our in vivo
data showed that CFU levels were not different between mice
receiving MAb to GlcCer and controls, suggesting that direct
fungal cytotoxicity by the MAb was minimal during early in-
fection. Nevertheless, in comparison to controls, mice given
MAb to GlcCer had dramatically reduced lung inflammatory
responses. These observations suggest that the MAb-mediated
protection may be a consequence of downregulation of the
inflammatory response. We therefore believe that in the pres-
ence of the antibodies to GlcCer, inflammatory responses are
better controlled by the host, resulting in reduced damage to
host tissues and more effective killing of the invading organism
by host effector cells (4). Similar results were described for
mice passively immunized with a protective IgG1 to GXM
prior to infection with C. neoformans (14, 32). The finding of
reduction of inflammation by nonopsonic antibody has also
been shown with other pathogenic fungi, such as Histoplasma
capsulatum (26).
The reduced inflammation in mice treated with the MAb to
GlcCer corresponds to the increased lung concentrations of
IL-4 on day 1 postinfection and anti-inflammatory cytokines,
such as IL-4 and IL-6 (28), on day 7. It has been shown that
IL-4 is necessary for MAb-mediated protection and that mice
genetically deficient in IL-6 and IL-12 production have in-
creased susceptibility to C. neoformans infections (2). In addi-
FIG. 2. Histology of lungs 1 day and 7 days after i.t. infection with C. neoformans. Mice were treated 1 day prior to infection with a MAb to
GlcCer or an irrelevant isotype-matched MAb. The pulmonary histology of mice receiving PBS instead of antibody prior to infection appeared
similar to that for mice receiving the irrelevant antibody. Images are representative of similar sections from mice in each group. Numerous C.
neoformans yeast cells were clearly visible in each section. Original magnification,100. A determination of the total number of cells in each system
(right panels) reveals a significant decrease in cellularity when mice were treated with anti-GlcCer before fungal infection. P values originated from
the statistical comparison (analysis of variance) of data obtained from mice given anti-GlcCer, and results for those given the control MAb or PBS
are shown.
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tion, an association between high levels of IL-6 and resistance
to C. neoformans infection has been recently described (37).
Administration of MAb to GlcCer in our cryptococcal model
also increased lung expression of IL-12 and IL12p70 on days 1
and 7 postinfection. IL-12 has in fact been demonstrated to
have a protective effect against pulmonary infections with C.
neoformans in mice (17). The elevated levels of RANTES in
the lungs of mice given MAb to GlcCer were in accordance
with results from a study by Uicker et al., which demonstrated
that this chemokine is associated to a protective cell-mediated
immunity against C. neoformans (40). On day 7, pulmonary
levels of MCP-5 and stem cell factor were also elevated, a
finding which may be correlated with the recruitment of
monocytic cells. These results reinforce the complexity of
the mechanisms through which antibodies modulate infec-
tion by C. neoformans.
Cerebroside expression is associated with virulence in pul-
monary cryptococcosis (31), which suggested that antibodies to
GlcCer could be efficacious in modifying disease. In summary,
as recently theorized by Mitchell (21), GlcCer represents a
valuable target for new therapeutic agents against cryptococ-
cosis. Considering the fact that fungal cerebrosides are ex-
tremely conserved and expressed in virtually all pathogenic
species studied so far (1), GlcCer-binding antibodies may also
be useful tools in the control of other mycoses.
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